Skip to main content

Table 1 Clinical characteristics on admission of patients with PDRP

From: Hyponatremia is a surrogate marker of poor outcome in peritoneal dialysis-related peritonitis

 

Hyponatremic group (n = 27)

Normonatremic group (n = 72)

p-value

Gender (M/F)

10/17

48/24

0.015

Age (years)

49.1 ± 9.9

52.6 ± 11.7

0.173

Duration of dialysis (years)

4.0 ± 1.5

3.4 ± 1.8

0.148

Primary renal disease

   

  Chronic glomerulonephritis

4

15

0.696

  Diabetic nephropathy

9

28

0.783

  Hypertension

8

13

0.328

  Systemic lupus erythematosus

3

7

1.000

  Polycystic kidney disease

0

1

1.000

  Unknown

3

8

1.000

Medication

   

  Oral Hypoglycemic agent

1

3

1.000

  α-adrenergic blocker

6

8

0.197

  β-adrenergic blocker

6

22

0.724

  Calcium channel blocker

15

27

0.164

  ACEI or ARB+

5

7

0.185

  Furosemide

2

6

1.000

  Na+ supplement

0

0

1.000

Number of 4.25% Dialysate (bags/day)

1.2 ± 0.8

1.0 ± 0.7

0.144

Duration before antibiotics delivery (day)

1.1 ± 0.5

1.1 ± 0.8

0.148

Co-morbidity: Deyo-CCI++

3.6 ± 1.2

3.7 ± 1.5

0.755

Subjective global assessment score

4.6 ± 1.2

5.7 ± 0.6

<0.001

Nutritional status: mean nPNA*

1.1 ± 0.3

1.2 ± 0.4

0.278

RRF** (mL/min/1.73 m2)

1.2 ± 1.4

1.5 ± 1.5

0.257

  1. +ACEI or ARB, Angiorensin-convering enzyme inhibitor or Angiotensin-II receptor blocker, ++Deyo-CCI, Deyo-charlson comorbidity index, *mean nPNA (mg/kg/day), the 6-month average of normalized protein nitrogen appearance, **RRF, residual renal function.